Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Neurosurgical Focus

• Publication date

  2007-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3171/FOC-07/10/E9PMID 17961046
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells

  2008cited by this paper
• Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas.

  2007cited by this paper
• HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.

  2007cited by this paper
• Effects of HIV Protease Inhibitor Ritonavir on Akt-Regulated Cell Proliferation in Breast Cancer

  2006cited by this paper
• Salvage chemotherapy With CPT-11 for recurrent meningioma

  2006cited by this paper
• Phase II study of imatinib mesylate (ST1571) for patients with recurrent meningiomas (NABTC 01-08)

  2006cited by this paper
• HIV‐1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling

  2005cited by this paper
• Epidemiology of intracranial meningioma.

  2005cited by this paper
• Induction of apoptosis in primary meningioma cultures by fenretinide.

  2005cited by this paper
• Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.

  2005cited by this paper
• [Hydroxyurea treatment for unresectable meningioma].

  2004cited by this paper
• Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells

  2004cited by this paper
• Lovastatin is a Potent Inhibitor of Meningioma Cell Proliferation: Evidence for Inhibition of a Mitogen Associated Protein Kinase

  2004cited by this paper
• Meningioma: an update

  2004cited by this paper
• HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2.

  2004cited by this paper
• Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.

  2004cited by this paper
• Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up

  2004cited by this paper
• Targeting the Platelet-Derived Growth Factor Receptor in Antivascular Therapy for Human Ovarian Carcinoma

  2004cited by this paper
• HIV-1 Protease Inhibitor, Ritonavir

  2004cited by this paper
• Meningiomas.

  2004cited by this paper
• Traitement des méningiomes par hydroxyurée

  2004cited by this paper
• Non-Resectable Slow-Growing Meningiomas Treated by Hydroxyurea

  2004cited by this paper
• Antitumour effects of antiretroviral therapy

  2004cited by this paper
• Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer

  2004cited by this paper
• Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro

  2003cited by this paper
• New approaches for the treatment of refractory meningiomas.

  2003cited by this paper
• Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.

  2003cited by this paper
• Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.

  2003cited by this paper
• STI-571: an anticancer protein-tyrosine kinase inhibitor.

  2003cited by this paper
• The effect of ursodeoxycholic acid on the survivin in thapsigargin-induced apoptosis.

  2003cited by this paper
• The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.

  2003cited by this paper
• Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma.

  2003cited by this paper
• Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.

  2002cited by this paper
• The treatment of malignant meningioma with verotoxin.

  2002cited by this paper
• Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis.

  2002cited by this paper
• The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.

  2002cited by this paper
• Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography.

  2001cited by this paper
• Meningioma treated with interferon-α, evaluated with [11C]-L-methionine positron emission tomography

  2001cited by this paper
• Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas.

  2001cited by this paper
• Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.

  2001cited by this paper
• Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice.

  2001cited by this paper
• Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.

  2000cited by this paper
• Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

  2000cited by this paper
• Expression of Estrogen Receptors Alpha and Beta in Human Meningiomas

  1999cited by this paper
• Mechanism of action and in vivo role of platelet-derived growth factor.

  1999cited by this paper
• Meningiomas

  1997cited by this paper
• Activation of p53-p21 waf1 Pathway in Response to Disruption of Cell-Matrix Interactions*

  1997cited by this paper
• Mechanism of action of platelet-derived growth factor.

  1996cited by this paper
• Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop

  1995cited by this paper
• Platelet-derived growth factor expression and stimulation in human meningiomas.

  1994cited by this paper
• Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.

  1991cited by this paper
• Recurrence of intracranial meningiomas, with special reference to radiotherapy.

  1980cited by this paper

• Small Molecule Inhibitors Targeting the "Undruggable" Survivin: The Past, Present, and Future from a Medicinal Chemist's Perspective.

  2023cites this paper
• Survivin Small Molecules Inhibitors: Recent Advances and Challenges

  2023cites this paper
• Preclinical Models of Meningioma.

  2023cites this paper
• Mouse Models in Meningioma Research: A Systematic Review

  2021cites this paper
• New drugs are not enough-drug repositioning in oncology: An update

  2020cites this paper
• The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir

  2020cites this paper
• Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo

  2019cites this paper
• Therapeutic strategies involving survivin inhibition in cancer

  2018cites this paper
• HIV‐protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO‐hybridized derivatives?

  2017cites this paper
• Targeting survivin for therapeutic discovery: past, present, and future promises.

  2017cites this paper
• Recent advances in the management of atypical meningiomas.

  2016cites this paper
• Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity

  2015cites this paper
• Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity.

  2015cites this paper
• Chromosomal alterations, prognostic factors, and targeted molecular therapies for malignant meningiomas.

  2013cites this paper
• The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro

  2013cites this paper
• Recent developments in chemotherapy for meningiomas: a review.

  2013cites this paper
• Caspase-3 and Survivin Expression in Primary Atypical and Malignant Meningiomas

  2013cites this paper
• Management of Malignant Meningiomas

  2012cites this paper
• Intracranial meningioma in mice: Noninvasive bioluminescence imaging

  2012cites this paper
• Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function

  2011cites this paper
• Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism

  2011influential citation
• Olfactory groove meningioma.

  2011cites this paper
• The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.

  2011cites this paper
• The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments

  2011cites this paper
• Medical therapies for meningiomas

  2010cites this paper
• Advances in meningioma therapy

  2009cites this paper
• Repositioning HIV protease inhibitors as cancer therapeutics

  2008cites this paper
• We are IntechOpen, the world’s leading publisher of Open Access books Built by scientists, for scientists

  year unknowncites this paper